Results 271 to 280 of about 765,049 (358)

From Smog to Scar: Epigenetic Signatures of Air Pollution in Interstitial Lung Disease. [PDF]

Am J Respir Crit Care Med
Konigsberg IR, Warburton D.
europepmc   +1 more source

UTILITY OF HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN ASSESSMENT OF INTERSTITIAL LUNG DISEASE

Manish Bhagat, Prachi Bamniya, Deepal Nema   +2 more
openalex   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Association of Health-Related Quality of Life with Functional and Radiological Outcomes in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease, Systemic Sclerosis-Associated Interstitial Lung Disease, and Idiopathic Pulmonary Fibrosis. [PDF]

Arch Rheumatol
Sahinoğlu I, Kizilirmak D, Uslu S, Kacar M, Tasgöz FC, Sülükcü S, Acar EA, Tuluy MG, Sari S, Soysal Gündüz O, Pirildar T.   +10 more
europepmc   +1 more source

Increased calcification by erythrophagocytosis in aortic valvular interstitial cells

ESC Heart Failure, Volume 12, Issue 2, Page 1469-1473, April 2025.
Abstract Background Calcific aortic valve disease (CAVD) progresses over time to severe aortic stenosis and eventually heart failure. Recent evidence indicates that intraleaflet haemorrhage (ILH) strongly promotes CAVD progression. However, it remains poorly understood how it mechanistically contributes to valvular calcification.
Zihan Qin, Magnus Bäck, Anders Franco‐Cereceda, Sven‐Christian Pawelzik   +3 more
wiley   +1 more source

Comprehensive analysis of patients with rheumatoid arthritis associated interstitial lung disease. [PDF]

Korean J Intern Med
Kim JW, Jung JY, Suh CH, Kim HA.
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Telomere Shortening in Interstitial Lung Disease: Challenges and Promises. [PDF]

Clin Respir J
Jin H, Song J, Gao R, Sha B, Wang S, Luo P, Yu L, Xu X, Wang X.   +8 more
europepmc   +1 more source

Causal correlations between inflammatory proteins and heart failure: A two‐sample Mendelian randomization analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1374-1385, April 2025.
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu, Gui‐Qin Liu, Ya‐Ping Peng, Li‐Ling Zhang, Xian‐Jin Wang, Liang‐Chuan Chen, Yuan‐Xi Zheng, Xue‐Jun Xiang, Rui Qiao, Xian‐He Lin   +9 more
wiley   +1 more source

How to handle IPF – the new Portuguese consensus document

Revista Portuguesa de Pneumologia (English Edition), 2016
Ulrich Costabel, Francesco Bonella
doaj   +1 more source